Genocea Biosciences Inc. (NASDAQ:GNCA) shares rose 2.7% during mid-day trading on Friday . The company traded as high as $4.98 and last traded at $4.95, with a volume of 67,566 shares changing hands. The stock had previously closed at $4.82.

GNCA has been the topic of a number of research analyst reports. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.95.

The firm has a 50 day moving average price of $4.32 and a 200-day moving average price of $4.32. The firm’s market cap is $142.52 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. On average, analysts anticipate that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.